Application of 2”-O-galloyl-seridin in the preparation of drugs for the treatment and / or relief of thyroid-associated ophthalmopathy

By regulating the pathological process of orbital fibroblasts in TAO patients with 2”-O-galloyl-seridin, this study addresses the limitations of existing TAO treatments and provides an effective and less side-effect-prone drug option for treating and alleviating thyroid-associated ophthalmopathy.

CN117323344BActive Publication Date: 2026-11-17THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIV
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202311112191.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-08-31
Publication Date
2026-11-17
Estimated Expiration
2043-08-31

AI Technical Summary

Technical Problem

Current treatment options for TAO are limited, especially for chronic TAO which lacks effective drugs. Existing anti-inflammatory treatments cannot solve core problems such as exophthalmos and have significant side effects.

Method used

By utilizing 2”-O-galloyl-seridin to regulate the pathological processes of orbital fibroblasts in TAO patients, including inhibiting cell proliferation, adipogenic differentiation, hyaluronic acid synthesis and secretion, and fibrosis, the disease can exert therapeutic and alleviating effects on thyroid-associated ophthalmopathy through a non-immunosuppressive pathway.

Benefits of technology

It effectively inhibits the pathological process of orbital fibroblasts in TAO patients, has a good immunomodulatory effect, can alleviate and treat thyroid-associated eye disease, and provides a safer treatment option.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117323344B_ABST
    Figure CN117323344B_ABST
Patent Text Reader

Abstract

This invention discloses a novel use of 2”-O-galloyl-gistrin. 2”-O-galloyl-gistrin can effectively regulate various pathological processes of orbital fibroblasts in patients with thyroid-associated ophthalmopathy (TAO), including excessive proliferation, lipid differentiation, fibrosis, and hyaluronic acid synthesis and secretion. It has good immunomodulatory effects and can alleviate and / or treat TAO through non-immunosuppressive pathways. It can be used to prepare drugs for the treatment and / or alleviation of thyroid-associated ophthalmopathy.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention belongs to the field of pharmaceutical technology and relates to the use of 2”-O-galloylgistrin in the preparation of drugs for treating and / or alleviating thyroid-related eye diseases. Background Technology

[0002] Thyroid-associated ophthalmopathy (TAO) is the most common extrathyroidal manifestation of toxic diffuse goiter (also known as Graves' disease). TAO is present in 25%–50% of Graves' disease patients, primarily affecting young and middle-aged adults, making it the most prevalent orbital disease in adults. The main clinical manifestations of TAO include exophthalmos, strabismus, and blepharoplasty. These changes in appearance and eye discomfort have a long-term impact on patients' mental health and quality of life. In severe cases, corneal exposure and optic nerve compression can occur, even leading to blindness and severely impairing social functioning. Therefore, the medical market demand for TAO treatment drugs is enormous. However, current treatment options for TAO are limited. For active TAO, intravenous corticosteroid pulse therapy, as a first-line treatment, has an efficacy rate of only about 60% and significant side effects. For chronic TAO, there are currently no effective drug treatments, and mainstream anti-inflammatory therapies cannot address the core issues such as exophthalmos, resulting in generally poor efficacy, with 15% of cases progressing to the next stage. Therefore, exploring targeted treatments for TAO is a pressing challenge and a hot topic in this field.

[0003] Existing research indicates that orbital fibroblasts (OFs) play a crucial role in the pathological process of transorbital ophthalmopathy (TAO) and are a core pathological mechanism in its development. Therefore, inhibiting the adipogenic differentiation and fibrosis of OFs holds promise for alleviating or reversing tissue remodeling, representing a key breakthrough in the treatment of TAO.

[0004] 2”-O-galloylhyperin (CAS: 53209-27-1) can be extracted from plants such as Pyrrosia lingua and Euphorbia helioscopia, and has a wide range of sources. Its structural formula is shown in Formula I below:

[0005]

[0006] Existing studies have shown that 2”-O-galloyl-seridin has a significant protective effect against myocardial ischemia-reperfusion injury. At the same time, it also has strong tannin activity, antioxidant activity, and the ability to eliminate lipid peroxidation free radicals and inhibit lipid peroxidation activity. Summary of the Invention

[0007] The purpose of this invention is to provide a new use for 2”-O-galloyl girdinoside.

[0008] According to one aspect of the invention, the use of 2”-O-galloyl kilocaloryl glycoside in the preparation of a medicament having an effect of inhibiting at least one of the following pathological processes of fibroblasts is provided:

[0009] (1) Cell proliferation;

[0010] (2) Adipogenic differentiation;

[0011] (3) Synthesis and secretion of hyaluronic acid;

[0012] (4) Fibrosis.

[0013] Through extensive experiments and research, the inventors discovered that 2”-O-galloyl-sericin can effectively regulate various pathological processes of orbital fibroblasts in TAO patients, including excessive proliferation, lipid differentiation, fibrosis, and hyaluronic acid synthesis and secretion. It has a good immunomodulatory effect and can alleviate and / or treat TAO through non-immunosuppressive pathways. It can be used to prepare drugs for the treatment and / or relief of thyroid-associated ophthalmopathy.

[0014] In some implementations, the medicament for treating and / or alleviating thyroid-associated ophthalmopathy may include 2”-O-galloylgidate and one or more pharmaceutically acceptable excipients.

[0015] In some embodiments, pharmaceutically acceptable excipients include, but are not limited to: solvents, solubilizers, binders, disintegrants, fillers, lubricants, wetting agents, osmotic pressure regulators, flavoring agents, pH regulators, thickeners, stabilizers, etc.

[0016] In some implementations, the drug can be administered orally, intravenously, intraperitoneally, subcutaneously, or transdermally.

[0017] In some embodiments, the dosage form of the drug may be an injection, an oral preparation, a spray, or an inhaler.

[0018] In some implementations, the drug may be in the form of an oral medication.

[0019] In some embodiments, the oral dosage form may be selected from at least one of tablets, granules, oral liquids, and capsules.

[0020] In some implementations, the oral dosage form may be a tablet.

[0021] In some embodiments, the content of 2”-O-galloyl gidarone in the tablet may be 20 mg / tablet. Attached Figure Description

[0022] Figure 1Figure 1 shows the results of CKK8 assay on the effect of different concentrations of 2”-O-GH on fibroblast cell viability.

[0023] Figure 2 The figure shows the results of EdU detection of the effect of different concentrations of 2”-O-GH on fibroblast proliferation. * P<0.05; ** P<0.01;

[0024] Figure 3 The figure shows the results of different concentrations of 2”-O-GH inhibiting fibroblast differentiation. * P<0.05; ** P<0.01; *** P<0.001;

[0025] Figure 4 The figure shows the results of different concentrations of 2”-O-GH inhibiting hyaluronic acid secretion from fibroblasts. * P<0.05;

[0026] Figure 5 The figure shows the results of different concentrations of 2”-O-GH inhibiting fibroblast fibrosis. * P<0.05; ** P<0.01. Detailed Implementation

[0027] The present invention will be further described in detail below with reference to the embodiments. The embodiments are for illustrative purposes only and do not limit the invention in any way. Unless otherwise specified, the raw materials and reagents used in the embodiments are conventional products that can be obtained commercially; experimental methods that do not specify specific conditions in the embodiments are generally performed under conventional conditions in the art or according to the conditions recommended by the manufacturer.

[0028] Example 1: Pharmacological Experiment

[0029] 1. Materials and Reagent Kits

[0030] Proliferation medium: DMEM-F12 (Gibco Laboratories, USA) containing 10% (vol / vol) fetal bovine serum;

[0031] Differentiation medium and Oil Red O staining solution: commercially available liposome induction medium (Celera, Guangzhou, China);

[0032] Cell counting kit-8 (CCK-8) cell proliferation kit (KGI, Guangzhou, China);

[0033] EdU DNA Synthesis Detection Kit (Raybot, Guangzhou, China);

[0034] Hyaluronic acid ELISA kit (Echelon Bioscience Inc., USA);

[0035] 2”-O-galloyl-sericin raw material (Solepro: YZ-111629, China): The powder is mixed with ultrapure water to prepare a 100mM stock solution, which is then diluted to 5, 20 and 50 μM for in vitro cell treatment.

[0036] 2”-O-galloylgistridine (2”-O-GH) inhibits the proliferation of OFs in TAO patients.

[0037] (1) Orbital free radicals (OFs) were extracted from the orbits of TAO patients (n=6) and passaged in proliferation medium to P2 for experiments. The patients were divided into different 2”-O-GH treatment groups (0, 5, 20, 50, 100, and 200 μM). After the start of treatment, the same concentration of CCK8 was added for three consecutive days, and the absorbance (450 nm) was measured after 4 hours of incubation. The results are as follows: Figure 1 As shown, cell activity gradually decreased with increasing 2”-O-GH concentration and prolonged treatment time. The concentrations of 2”-O-GH (0, 5, 20, 50 μM) with no cytotoxicity were selected as the experimental subjects.

[0038] (2) OFs were extracted from the orbits of TAO patients (n=5), passaged to P2 in proliferation medium for experiments, and after synchronization treatment, they were divided into 4 groups of 2”-O-GH (0, 5, 20, 50 μM) under induced lipidolysis medium. EdU was then added and incubated at 37℃ for 18 h. After cell fixation, staining was performed, and the images were taken with a fluorescence microscope. The EdU positive rate was counted.

[0039] (3) Experimental Results

[0040] The results are as follows Figures 1-2 As shown.

[0041] Excessive proliferation of OFs is one of the pathophysiological mechanisms of TAO. To verify whether 2”-O-GH affects its proliferation, this invention extracted OFs from TAO patients. After treating the OFs with different concentrations of 2”-O-GH in proliferation medium, CCK8 cell viability experiments were performed. The results showed that excessive 2”-O-GH inhibited OF proliferation in a time- and concentration-dependent manner. Figure 1 .

[0042] Depend on Figure 1The results showed that 2”-O-GH concentrations exceeding 50 μM exhibited significant cytotoxicity. Therefore, subsequent experiments used 2”-O-GH concentrations of 5, 20, and 50 μM. Further analysis using EdU (5-ethynyl-2'-deoxyuridine) cell proliferation assays to detect DNA synthesis revealed statistically significant differences in the EdU-positive rate compared to the control group, indicating that 2”-O-GH (20 and 50 μM) significantly inhibited OF cell proliferation.

[0043] 3. 2”-O-galloyl-glucosinolate (2”-O-GH) inhibits esterification differentiation of OFs in TAO patients.

[0044] (1) OFs were extracted from the orbits of TAO patients (n=5) and passaged to P3 in proliferation medium. When the cell density reached more than 90%, the induction medium was changed and the cells were divided into 4 groups of 2”-O-GH (0, 5, 20, 50 μM). After 10 days, the cells were fixed and ordinary phase contrast images and Oil Red O stained images (100×) were taken with an optical microscope.

[0045] (2) After successful induction of differentiation for 4 days, cells from each group were collected to extract proteins and perform immunoblotting experiments to detect changes in markers related to adipogenic differentiation.

[0046] (3) Experimental Results

[0047] The results are as follows Figure 3 As shown.

[0048] The exophthalmos symptoms in TAO patients are mainly caused by the compression of periorbital tissue by the adipogenic differentiation of OFs. To verify whether 2”-O-GH has any effect on the above-mentioned pathological process of OFs, this invention induces the differentiation of OFs in TAO patients and cultured them, while treating them with 2”-O-GH (5, 20, 50 μM) or using an untreated control. The adipogenic differentiation capacity of OFs was detected by Oil Red staining and immunoblotting.

[0049] Depend on Figure 3 The results showed that 2”-O-GH (20, 50 μM) could inhibit lipid droplet formation. Meanwhile, the results of immunoblotting showed that the expression levels of markers PPARγ, Perilipin-1 (PELN1), FABP4, and CEBPα in the pre- and mid-adipogenic stages were downregulated by 2”-O-GH (20, 50 μM), indicating that 2”-O-GH (20, 50 μM) could significantly inhibit the adipogenic differentiation of OFs.

[0050] 3. 2”-O-galloyl-glucosinolate (2”-O-GH) inhibits the secretion of hyaluronic acid by OFs in patients with TAO.

[0051] (1) OFs were extracted from the orbits of TAO patients (n=4) and passaged to P3 in proliferation medium. When the cell density reached more than 90%, the induction medium was changed and the cells were divided into 4 groups of 2”-O-GH (0, 5, 20, 50 μM). The cells were treated for 48 h. The supernatant of the medium was collected, and after centrifugation at 4°C to remove dead cells, the hyaluronic acid concentration was detected by enzyme-linked immunosorbent assay (ELISA) kit.

[0052] (2) Experimental Results

[0053] like Figure 4 As shown.

[0054] Hyaluronic acid is the main hydrophilic mucopolysaccharide in the orbit of patients with TAO, which promotes the increase of periorbital contents and compresses surrounding tissues, and its secretion increases significantly under the stimulation of induction culture medium.

[0055] ELISA results showed that 2”-O-GH (50μM) significantly inhibited hyaluronic acid secretion.

[0056] 4. 2”-O-galloyl-glucosidin (2”-O-GH) inhibits OFs fibrosis in TAO patients.

[0057] (1) OFs were extracted from the orbits of TAO patients (n=7) and passaged to P3 in proliferation medium. When the cell density reached more than 90%, TGF-β1 (10ng / mL) was added to induce fibrosis. The cells were divided into 4 groups of 2”-O-GH (0, 5, 20, 50μM) and treated for 72h. The fibrosis markers collagen type I (COL1A1) and α-smooth muscle actin (α-SMA) were stained.

[0058] (2) Experimental Results

[0059] like Figure 5 As shown.

[0060] OFs fibrosis is an important pathological mechanism for orbital tissue remodeling and chronicity in TAO patients, promoting the increase of periorbital contents and compressing surrounding tissues.

[0061] The results showed that 2”-O-GH could inhibit OFs fibrosis.

[0062] The above descriptions are merely some embodiments of the present invention. Those skilled in the art can make various modifications and improvements without departing from the inventive concept of the present invention, and these all fall within the scope of protection of the present invention.

Claims

1. 2''-O-galloyl-seridin in the preparation of drugs for relieving and / or treating thyroid-associated ophthalmopathy.

2. Use according to claim 1, characterized in that, The drug comprises 2''-O-galloyl kilocalorie and one or more pharmaceutically acceptable excipients.

3. Use according to claim 2, characterized in that, The excipients are selected from at least one of solvents, solubilizers, binders, disintegrants, fillers, lubricants, wetting agents, osmotic pressure regulators, flavoring agents, and stabilizers.

4. The application according to claim 3, characterized in that, The excipients also include pH adjusters and / or thickeners.

5. The application according to claim 2 or 3, characterized in that, The drug may be administered orally, intravenously, intraperitoneally, subcutaneously, or transdermally.

6. The application according to claim 5, characterized in that, The dosage form of the drug is injection, oral, spray, or inhalation.

7. The application according to claim 6, characterized in that, The drug is in the form of an oral medication.

8. The application according to claim 7, characterized in that, The oral preparation is selected from at least one of tablets, granules, oral liquids, and capsules.

9. The application according to claim 8, characterized in that, The oral medication is a tablet.

Citation Information

Patent Citations

  • Application of 2 ''-O-galloyl hyperoside in preparation of anti-fibrosis drugs

    CN117398399A